Revenue + Forward P/E
CRISPR Therapeutics AG (CRSP) quarterly revenue and forward P/E
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$5.19B
Enterprise value
$5.55B
P/E ratio (TTM)
-11.02x
P/S ratio (TTM)
377.74x
P/B ratio
2.90x
EV/Sales
414.51x
EV/EBITDA
-12.23x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$3.51M
Gross profit (TTM)
$-229.45M
Operating income (TTM)
$-568.32M
EBITDA (TTM)
$-558.49M
Net income (TTM)
$-581.60M
Free cash flow (TTM)
$-345.93M
Margins & returns
Gross margin
-1534.39%
Operating margin
-3971.53%
Profit margin
-3368.72%
Return on equity
-24.39%
Return on assets
-17.02%
Per-share metrics
EPS (TTM)
-$4.67
Dividend yield
0.00%
Beta
1.70
Capital structure
Cash & equivalents
$355.19M
Total debt
$394.91M
Net debt
$39.73M
Shares outstanding
96.45M
Financial health
Current ratio
13.32
Debt / equity
0.21
Debt / assets
0.17
Interest coverage
-
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.14T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.63B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $442.09B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.28B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.83B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $5.19B | -11.02x | 377.74x | -12.23x | - |